<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:04:46Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5430537" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5430537</identifier><datestamp>2017-05-15</datestamp><setSpec>scirep</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
      <journal-title-group>
        <journal-title>Scientific Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2045-2322</issn>
      <publisher>
        <publisher-name>Nature Publishing Group UK</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5430537</article-id>
      <article-id pub-id-type="pmcid">PMC5430537</article-id>
      <article-id pub-id-type="pmc-uid">5430537</article-id>
      <article-id pub-id-type="pmid">28428547</article-id>
      <article-id pub-id-type="pmid">28428547</article-id>
      <article-id pub-id-type="publisher-id">1129</article-id>
      <article-id pub-id-type="doi">10.1038/s41598-017-01129-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The tarantula toxin <italic>Î²</italic>/<italic>Î´-TRTX-Pre1a</italic> highlights the importance of the S1-S2 voltage-sensor region for sodium channel subtype selectivity</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Wingerd</surname>
            <given-names>Joshua S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mozar</surname>
            <given-names>Christine A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ussing</surname>
            <given-names>Christine A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Murali</surname>
            <given-names>Swetha S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chin</surname>
            <given-names>Yanni K.-Y.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cristofori-Armstrong</surname>
            <given-names>Ben</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Durek</surname>
            <given-names>Thomas</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gilchrist</surname>
            <given-names>John</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4314-7689</contrib-id>
          <name>
            <surname>Vaughan</surname>
            <given-names>Christopher W.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bosmans</surname>
            <given-names>Frank</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7030-2288</contrib-id>
          <name>
            <surname>Adams</surname>
            <given-names>David J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lewis</surname>
            <given-names>Richard J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alewood</surname>
            <given-names>Paul F.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2420-4262</contrib-id>
          <name>
            <surname>Mobli</surname>
            <given-names>Mehdi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0622-609X</contrib-id>
          <name>
            <surname>Christie</surname>
            <given-names>Macdonald J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3616-0279</contrib-id>
          <name>
            <surname>Rash</surname>
            <given-names>Lachlan D.</given-names>
          </name>
          <address>
            <email>l.rash@uq.edu.au</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.1003.2</institution-id><institution>Institute for Molecular Bioscience, </institution><institution>The University of Queensland, </institution></institution-wrap>St Lucia, QLD 4072 Australia </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.1003.2</institution-id><institution>Centre for Advanced Imaging &amp; School of Chemistry and Molecular Biosciences, </institution><institution>The University of Queensland, </institution></institution-wrap>St Lucia, QLD 4072 Australia </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.1003.2</institution-id><institution>School of Biomedical Sciences, </institution><institution>The University of Queensland, </institution></institution-wrap>St Lucia, 4072 QLD Australia </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution>Discipline of Pharmacology, </institution><institution>University of Sydney, </institution></institution-wrap>Camperdown, NSW 2006 Australia </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution>Pain Management Research Institute, </institution><institution>University of Sydney, </institution></institution-wrap>St Leonards, NSW 2006 Australia </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.1007.6</institution-id><institution>Illawarra Health and Medical Research Institute, </institution><institution>University of Wollongong, </institution></institution-wrap>Wollongong, NSW 2522 Australia </aff>
        <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution>Department of Physiology and Solomon H. Snyder Department of Neuroscience, </institution><institution>Johns Hopkins University School of Medicine, </institution></institution-wrap>Baltimore, Maryland 21205 USA </aff>
        <aff id="Aff8"><label>8</label>Novo Nordisk A/S, Copenhagen Area, Capital Region, Denmark </aff>
        <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution>Harvard Medical School, </institution><institution>Childrenâs Hospital, </institution></institution-wrap>300 Longwood Ave, Boston, MA 02115 United States </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>4</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>20</day>
        <month>4</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2017</year>
      </pub-date>
      <volume>7</volume>
      <elocation-id>974</elocation-id>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>12</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>3</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the articleâs Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the articleâs Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Voltage-gated sodium (Na<sub>V</sub>) channels are essential for the transmission of pain signals in humans making them prime targets for the development of new analgesics. Spider venoms are a rich source of peptide modulators useful to study ion channel structure and function. Here we describe Î²/Î´-TRTX-Pre1a, a 35-residue tarantula peptide that selectively interacts with neuronal Na<sub>V</sub> channels inhibiting peak current of hNa<sub>V</sub>1.1, rNa<sub>V</sub>1.2, hNa<sub>V</sub>1.6, and hNa<sub>V</sub>1.7 while concurrently inhibiting fast inactivation of hNa<sub>V</sub>1.1 and rNa<sub>V</sub>1.3. The DII and DIV S3-S4 loops of Na<sub>V</sub> channel voltage sensors are important for the interaction of Pre1a with Na<sub>V</sub> channels but cannot account for its unique subtype selectivity. Through analysis of the binding regions we ascertained that the variability of the S1-S2 loops between Na<sub>V</sub> channels contributes substantially to the selectivity profile observed for Pre1a, particularly with regards to fast inactivation. A serine residue on the DIV S2 helix was found to be sufficient to explain Pre1aâs potent and selective inhibitory effect on the fast inactivation process of Na<sub>V</sub>1.1 and 1.3. This work highlights that interactions with both S1-S2 <italic>and</italic> S3-S4 of Na<sub>V</sub> channels may be necessary for functional modulation, and that targeting the diverse S1-S2 region within voltage-sensing domains provides an avenue to develop subtype selective tools.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>Â© The Author(s) 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Voltage-gated sodium channels (Na<sub>V</sub>s) are membrane proteins with four homologous domains (DI-DIV), each composed of six transmembrane segments (S1-S6) assembled into a single, functional Î±-subunit (~260âkDa). Each domain has two functionally distinct regions; the S1-S4 segments comprise the voltage-sensing domain (VSD) whereas the S5-S6 helices and extracellular âP-loopâ form the selectivity filter and ion-conducting pore. There are nine mammalian Î±-subunits (Na<sub>V</sub>1.1 to Na<sub>V</sub>1.9) with greater than 64% sequence identity between isoforms 1.1 to 1.7, whereas 1.8 and 1.9 share ~50â60% identity with other members<sup><xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref></sup>. The Na<sub>V</sub> channel family contains important therapeutic targets for local anaesthetics, anti-arrhythmics, analgesics, and anti-epileptics<sup><xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref></sup>. For example, the peripherally expressed neuronal Na<sub>V</sub>1.7 has been identified as a potential target for the treatment of chronic pain, largely from studies of human channelopathies<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. Mutations of <italic>SCN9A</italic> that result in Na<sub>V</sub>1.7 gain-of-function underlie paroxysmal extreme pain disorder (PEPD) and primary erythromelalgia<sup><xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref></sup>, whereas mutations that result in the loss of Na<sub>V</sub>1.7 function underlie âcongenital insensitivity to painâ (CIP)<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. The neuronal isoforms Na<sub>V</sub>1.3, Na<sub>V</sub>1.8 and Na<sub>V</sub>1.9 have also been implicated in various forms of chronic and acute pain<sup><xref ref-type="bibr" rid="CR9">9</xref>â<xref ref-type="bibr" rid="CR12">12</xref></sup>, whereas recent evidence suggests that Na<sub>V</sub>1.1 also plays a role in mechanical pain transmission<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. However, the similarity between Na<sub>V</sub> channel Î±-subunits poses a challenge to discover and develop molecules that can selectively modify the function of each subtype.</p>
      <p>Natural toxins have been instrumental in defining Na<sub>V</sub> channel subtypes and many of the known functionally relevant binding sites on the channel<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. In recent decades, venom peptides have proven to be an invaluable source of novel, selective, and potent modulators of ion channels, leading to an increasing interest in these molecules as pharmacological tools and potential therapeutic leads<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. In this respect, spiders possibly represent one of the richest sources of novel voltage-gated channel modulators<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> that not only target channel Î±-subunits, but also complexes containing the accessory Î²-subunits<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. A majority of currently characterised Na<sub>V</sub> channel modulating spider venom peptides share a common structural motif of the inhibitory cysteine knot (ICK) and interact with one of four VSDs at partially defined receptor sites<sup><xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref></sup>.</p>
      <p>These VSD modulating peptides have been described to modify channel gating in three distinct ways depending on the domain they target and the effect on that domain<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Domain IV of the Na<sub>V</sub> channel Î±-subunit uniquely controls inactivation of the channel<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, thus spider peptides that interact with and hinder the normal function of VSDIV slow or inhibit fast inactivation of the channel and may result in persistent current<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Conversely, spider venom peptides that interact with DI, DII, and DIII VSD modulate channel activation<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Most of those discovered to date cause a shift in the voltage-dependence of activation in the depolarising direction and inhibit activation<sup><xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref></sup>, whereas some such as Î²-HXTX-Mg1a (Magi 5) cause a hyperpolarising shift, thereby facilitating activation<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. The VSDs of different voltage-gated ion channels exhibit higher sequence variability than the highly conserved pore region, thus offering the opportunity for subtype-selective interactions between Na<sub>V</sub> subtypes as well as the greater voltage-gated ion channel superfamily. Indeed, certain families of spider venom peptides demonstrate remarkable subtype selectivity profiles<sup><xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR25">25</xref></sup>.</p>
      <p>A deeper understanding of the molecular basis of the interactions between spider venom peptides with Na<sub>V</sub> channels is helping efforts to design a new generation of pharmacological tools and potential therapeutic lead molecules<sup><xref ref-type="bibr" rid="CR26">26</xref>â<xref ref-type="bibr" rid="CR28">28</xref></sup>. To this end, we identified Î²/Î´-TRTX-Pre1a (Pre1a) from the venom of the tarantula <italic>Psalmopoeus reduncus</italic> in a screen for Na<sub>V</sub>1.7 inhibitors. Pre1a exhibited a unique and complex pharmacological profile across neuronal Na<sub>V</sub> channel subtypes where it preferentially inhibits <italic>fast inactivation</italic> of Na<sub>V</sub>1.3, inhibits <italic>activation</italic> of Na<sub>V</sub>1.2, Na<sub>V</sub>1.6, and Na<sub>V</sub>1.7, and inhibits <italic>both</italic> activation and fast inactivation of Na<sub>V</sub>1.1, with no effect on Na<sub>V</sub>1.4 or Na<sub>V</sub>1.5 at sub-micromolar concentrations. This functional profile is dictated by classical interactions with the DII and DIV S3-S4 loops of the Na<sub>V</sub> channel VSDs. However, our evidence points to the S1-S2 loops as critical for imparting the isoform selectivity demonstrated by Pre1a. Pre1a thus represents a valuable tool to study the subtle differences in DII and DIV interaction sites between members of the Na<sub>V</sub> channel family.</p>
    </sec>
    <sec id="Sec2" sec-type="results">
      <title>Results</title>
      <sec id="Sec3">
        <title>Isolation and sequence of TRTX-Pre1a</title>
        <p>In a small screen of 14 spider venoms, <italic>Psalmopoeus reduncus</italic> venom at 1:1000 dilution (~200âÎ¼g/ml) consistently and potently inhibited human (h) Na<sub>V</sub>1.7 expressed in <italic>Xenopus laevis</italic> oocytes. Activity-guided fractionation resulted in the identification of a major component exhibiting inhibitory activity at hNa<sub>V</sub>1.7 expressed in oocytes (Fig.Â <xref rid="Fig1" ref-type="fig">1a</xref>). The purified peptide eluted with an unusual, leading minor peak that upon mass analysis revealed the same Mâ+âH<sup>+</sup> of 4227.5 as the principal peak (Fig.Â <xref rid="Fig1" ref-type="fig">1b</xref>) and was found to inhibit both the of peak current of hNa<sub>V</sub>1.7 and the inactivation of rat (r) Na<sub>V</sub>1.3 (Fig.Â <xref rid="Fig1" ref-type="fig">1c</xref>). The mass of the reduced/alkylated peptide was 588âDa higher than the native peptide (6âÃâ98, the MW of maleimide), indicating the presence of three disulfide bonds (data not shown). Edman analysis of the reduced/alkylated peptide resulted in complete sequence determination of a novel 35 amino acid peptide with high sequence similarity to several Na<sub>V</sub> modulating spider venom peptides (Fig.Â <xref rid="Fig1" ref-type="fig">1d</xref>), determined by a search of non-redundant protein database (NCBI). Sequences were aligned and percent similarity calculated manually. Taking into account disulfide bonds, the observed monoisotopic Mâ+âH<sup>+</sup> (4227.5) matched that of the theoretical Mâ+âH<sup>+</sup> with a free acid C-terminus (4226.9, Expasy-PeptideMass) that was confirmed using MSMS on tryptic digest fragments (data not shown). The peptide was named TRTX-Pre1a (Pre1a) according to the current rational nomenclature<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>.<fig id="Fig1"><label>Figure 1</label><caption><p>Identification and sequence of TRTX-Pre1a. (<bold>a)</bold> RP-HPLC chromatogram of crude venom from <italic>P. reduncus</italic> indicating the fraction (F18) responsible for robust inhibition of hNa<sub>V</sub>1.7 expressed in <italic>Xenopus</italic> oocytes (inset). (<bold>b)</bold> Final analytical RP-HPLC purification step of F18 (TRTX-Pre1a) (inset: MALDI-TOF MS spectrum showing Mâ+âH<sup>+</sup> of 4227.5). (<bold>c)</bold> Activity of pure, native Pre1a on rNa<sub>V</sub>1.3 and hNa<sub>V</sub>1.7 exressed in <italic>Xenopus</italic> oocytes demonstrating inhibition of inactivation and peak current, respectively. (<bold>d)</bold> Sequence alignment of TRTX-Pre1a with Na<sub>V</sub> modulating Theraphotoxins<sup><xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR47">47</xref>â<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR65">65</xref>â<xref ref-type="bibr" rid="CR68">68</xref></sup>. Percent similarity was calculated comparing the number of identical (dark gray) and similar (light gray) amino acids.</p></caption><graphic xlink:href="41598_2017_1129_Fig1_HTML" id="d29e823"/></fig>
</p>
        <p>In order to carry out functional characterisations, we produced Pre1a using Boc solid-phase peptide synthesis. The folded synthetic peptide co-eluted with the peptide isolated from the native source (Supp. Fig.Â <xref rid="MOESM1" ref-type="media">1</xref>). Analytical RP-HPLC analysis of synthetic Pre1a revealed that the unusual non-symmetrical nature of the eluting peptide is an inherent property of the peptide and suggested that Pre1a is structurally heterogeneous (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>). This structural heterogeneity was confirmed by collecting the body and trailing portions of the major peak as individual fractions then re-injecting under the same conditions, whereupon the same non-symmetrical chromatographic profile was observed (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref> insets). This suggests a conformational (chemical) exchange process that is slow on the HPLC time scale.<fig id="Fig2"><label>Figure 2</label><caption><p>Pre1a shows conformational flexibility under RP-HPLC conditions. Analytical RP-HPLC of pure synthetic Pre1a shows the presence of multiple conformers in and acetonitrile/water mixture at room temperature. Insets 1 and 2, demonstrate identical elution profiles for reinjection of two fractions (highlighted and numbered) taken from the major peak, discounting the presence of impurities.</p></caption><graphic xlink:href="41598_2017_1129_Fig2_HTML" id="d29e844"/></fig>
</p>
      </sec>
      <sec id="Sec4">
        <title>Structural studies of recombinant Pre1a</title>
        <p>Preliminary homonuclear NMR analysis of synthetic Pre1a confirmed the presence of conformational heterogeneity, prompting us to isotope label the peptide (using recombinant expression in <italic>E. coli</italic>, Supp. Fig.Â <xref rid="MOESM1" ref-type="media">2</xref>) to enable less ambiguous heteronculear NMR analysis. Backbone resonance assignments (<sup>1</sup>H<sub>N</sub>, <sup>15</sup>N, <sup>13</sup>C<sub>Î±</sub>, <sup>13</sup>C<sub>Î²</sub>, <sup>13</sup>Câ²) for rPre1a were completed by analysis of the 3D HNCACB, CBCA(CO)NH, and HNCO spectra, and the side chain <sup>1</sup>H and <sup>13</sup>C chemical shifts from the 3D H(CC) (CO)NH-TOCSY and (H)CC(CO)NH-TOCSY spectra, respectively. Together we achieved 90% completion of all proton assignments. However, due to the structural heterogeneity, insufficient unique constraints were derived from the NOESY spectra to enable the structure calculations using CYANA<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> to produce a adequately converged high-resolution structure. However, the chemical shifts determined for the backbone resonances allowed us to predict the secondary structure of Pre1a using the program TALOS+â<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>, which suggests that residues around C3âL4 and Y21âK22 are likely to form Î²-strands (Supp. Fig.Â <xref rid="MOESM1" ref-type="media">3a</xref>).</p>
        <p>Furthermore, the NMR data allowed us to confidently determine the disulfide connectivity of the peptide via unambiguous NOEs between sidechain C<sub>Î²</sub> filtered H<sub>Î²</sub> protons. NOEs could be observed between the side chain protons of C3 and C18, C10 and C23 and C17 and C30 in the <sup>13</sup>C-NOESY (Supp. Fig.Â <xref rid="MOESM1" ref-type="media">3b</xref>), consistent with the formation of the common ICK-motif (C1âC4, C2âC5, C3âC6), which appears to be the dominant structural scaffold among Na<sub>V</sub> channel modulating spider venom peptides characterised to date.</p>
        <p>The 3D NMR data also allowed us to characterise the conformational heterogeneity of Pre1a, first observed on RP-HPLC. The presence of several peptide conformations resulted in multiple backbone <sup>1</sup>H<sub>N</sub>/<sup>15</sup>N chemical shifts for residues D2âR9 in the <sup>15</sup>N-HSQC spectrum, exemplified by G5 (Fig.Â <xref rid="Fig3" ref-type="fig">3a</xref>). These residues form Loop 1 and, with the exception of S8 and R9 (which have duplicate peaks), all have visible triplicate peaks with decreasing intensities (for examples of NMR experiments on related but structurally rigid peptides see Fig.Â <xref rid="Fig2" ref-type="fig">2</xref> in Lau <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> and Fig.Â <xref rid="MOESM1" ref-type="media">S3</xref> in Klint <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>). Additionally, a homology model of Pre1a was constructed using the structure of HwTx-IV as a template (PDB 2M4X)<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> using SWISS-MODEL<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. The Pre1a model shows a highly dense packing of five aromatic residues with W6 and F7 at the tip of Loop 1 falling between W29 and Y32/Y21 on one face of the peptide (Fig.Â <xref rid="Fig3" ref-type="fig">3b</xref>). We hypothesise that this overcrowding of bulky aromatic side chains results in the structural flexibility of Pre1a as seen in both aqueous (NMR) and hydrophobic (RP-HPLC) conditions.<fig id="Fig3"><label>Figure 3</label><caption><p>Pre1a shows conformational flexibility in aqueous conditions. (<bold>a)</bold> 2D <sup>1</sup>H-<sup>15</sup>N-HSQC of recombinantly produced Pre1a. The chemical shifts of resonances for residues in loop 1 (D2âR9, <underline>underlined</underline>) show multiple peaks indicating the presence of three conformations of the peptide (Aâ=âMajor, Bâ=âmiddle, Câ=âminor, highlighted for G5 in the inset). scâ=âside chain NH resonances for N, R and W residues. (<bold>b)</bold> Two views of a homology model of Pre1a (based on the NMR structure of HwTxIV, PDB: 2M4X) illustrating the relative positions of W6 and F7 at the tip of Loop 1 and W29, Y32 and Y21. Loop 1 residues (that show multiple peaks in the HSQC above) are in red, disulfide bonds are in yellow. The right panel highlights the position of W6 and F7 at the tip of Loop 1 and the positions of C3 and R9, which may act as a hinge region for movement of the loop.</p></caption><graphic xlink:href="41598_2017_1129_Fig3_HTML" id="d29e990"/></fig>
</p>
      </sec>
      <sec id="Sec5">
        <title>Pre1a affects neuronal Na<sub>V</sub> channels in a subtype-dependent manner</title>
        <p>Pre1a produced by either chemical synthesis or recombinant expression was equipotent at inhibiting the peak current of hNa<sub>V</sub>1.7 (Supp. Fig.Â <xref rid="MOESM1" ref-type="media">4a</xref>). Î²-subunits can have profound effects on venom peptide interactions with Na<sub>V</sub> channels<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>, however Pre1aâs inhibitory effect on hNa<sub>V</sub>1.7 was not modified by the accessory Î²1 subunit (Supp. Fig.Â <xref rid="MOESM1" ref-type="media">4b</xref>). To determine the subtype selectivity profile of recombinant Pre1a it was tested on five different Na<sub>V</sub> channel Î±-subunits expressed in <italic>X. laevis</italic> oocytes (Fig.Â <xref rid="Fig4" ref-type="fig">4a</xref>). Pre1a concentration-dependently inhibited the peak inward current of rNa<sub>V</sub>1.2 and hNa<sub>V</sub>1.7 with IC<sub>50</sub> values of 189.6ânM (pIC<sub>50</sub> 6.72âÂ±â0.06) and 114.0ânM (pIC<sub>50</sub> 6.94âÂ±â0.06), respectively (Fig.Â <xref rid="Fig4" ref-type="fig">4b</xref>), and weakly inhibited rNa<sub>V</sub>1.3 with an IC<sub>50</sub> of 8.0âÎ¼M (pIC<sub>50</sub> 5.10âÂ±â0.05). Similar to its effect on Na<sub>V</sub>1.3, 1âÎ¼M Pre1a only weakly inhibited the peak current amplitude of rNa<sub>V</sub>1.4 and hNa<sub>V</sub>1.5 by 16.47âÂ±â0.05% and 8.60âÂ±â0.05%, respectively (Fig.Â <xref rid="Fig4" ref-type="fig">4b</xref>).<fig id="Fig4"><label>Figure 4</label><caption><p>Pre1a preferentially inhibits neuronal Na<sub>V</sub> channels. (<bold>a)</bold> Representative Na<sub>V</sub> currents recorded from <italic>Xenopus</italic> oocytes (Î±-subunit alone) before addition of 1âÂµM Pre1a (black) and after reaching steady state inhibition (red). Late current was assessed at 50âms (100âms for Na<sub>V</sub>1.3) from the peak current, as highlighted by the grey box on rNa<sub>V</sub>1.3. <bold>(b)</bold> Concentration-effect curves for peak current inhibition by Pre1a for rNa<sub>V</sub>1.2 (IC<sub>50</sub> 189.6ânM; nââ¥â5), rNa<sub>V</sub>1.3 (IC<sub>50</sub> 8.0âÎ¼M; nââ¥â8) and hNa<sub>V</sub>1.7 (IC<sub>50</sub> 114.0ânM; nââ¥â8), with single point 1âÂµM concentrations for rNa<sub>V</sub>1.4 (nâ=â6) and hNa<sub>V</sub>1.5 (nâ=â7). <bold>(c)</bold> Concentration-response curve for late current inhibition of inactivation by Pre1a of rNa<sub>V</sub>1.3 (EC<sub>50</sub> 45.0ânM). <bold>(d)</bold> Concentration-dependent effects of Pre1a on the rate of inactivation (Ï) for rNa<sub>V</sub>1.3, with 1âÂµM demonstrating a significant slowing of inactivation (pâ&lt;â0.001; nââ¥â5; ANOVA with Dunnetâs test). <bold>(e)</bold> Representative current traces of hNa<sub>V</sub>1.1, hNa<sub>V</sub>1.6, and hNa<sub>V</sub>1.7 expressed in HEK cells co-expressed with Na<sub>V</sub>Î²1, in the absence (black) and presence (red) of varying Pre1a concentrations. <bold>(f)</bold> Concentration-response curves for peak current inhibition by Pre1a for hNa<sub>V</sub>1.1 (IC<sub>50</sub> 57.1ânM; nââ¥â6), hNa<sub>V</sub>1.6 (IC<sub>50</sub> 221.6ânM; nââ¥â6), and hNa<sub>V</sub>1.7 (IC<sub>50</sub> 15.0ânM; nââ¥â9) expressed in HEK cells. <bold>(g)</bold> Concentration-response curves for Pre1a effects on late current (measured at 10âms from peak) of hNa<sub>V</sub>1.1 (EC<sub>50</sub> 41.4ânM), with no measurable effect on hNa<sub>V</sub>1.6 or hNa<sub>V</sub>1.7. <bold>(h)</bold> Concentration-dependent effects of Pre1a on the rate of inactivation (Ï) for hNa<sub>V</sub>1.1, with 30ânM and 300ânM demonstrating a significant slowing of inactivation (pâ&lt;â0.001; nââ¥â5; ANOVA with Dunnetâs test).</p></caption><graphic xlink:href="41598_2017_1129_Fig4_HTML" id="d29e1201"/></fig>
</p>
        <p>Pre1a demonstrated inhibitory effects on rNa<sub>V</sub>1.3 fast inactivation (Fig.Â <xref rid="Fig4" ref-type="fig">4a</xref>), thus these effects on Na<sub>V</sub>1.2, 1.3 and 1.7 were examined in detail. We analysed the rate of fast inactivation (defined as tau, Ï<sub>inact</sub>, or the time to reach 36.8% of a single exponential fit of the current decay) and the degree of persistent sodium current measured at 50âms of depolarisation (Na<sub>V</sub>1.2 and 1.7) and 100âms for rNa<sub>V</sub>1.3 due to the longer time required to reach complete inactivation in the oocyte expression system without Î²1. Consistent with results observed during assay-guided fractionation, Pre1a potently inhibited the inactivation of rNa<sub>V</sub>1.3 with an EC<sub>50</sub> of 45.5ânM (pEC<sub>50</sub> 7.34âÂ±â0.27) (Fig.Â <xref rid="Fig4" ref-type="fig">4a and c</xref>), a selectivity of more than 150-fold for inhibiting rNa<sub>V</sub>1.3 inactivation over activation. In addition to inhibiting the <italic>extent</italic> of rNa<sub>V</sub>1.3 inactivation (as indicated by the level of persistent current), Pre1a also decreased the <italic>rate</italic> of current inactivation, reflected as a concentration-dependent increase in Ï<sub>inact</sub> (Fig.Â <xref rid="Fig4" ref-type="fig">4d</xref>). At 1âÎ¼M, a concentration that almost completely inhibited rNa<sub>V</sub>1.2 and hNa<sub>V</sub>1.7 currents, Pre1a had no significant effect on the persistent current or Ï<sub>inact</sub> of either of these channels. There was no apparent effect of 1âÎ¼M Pre1a on the inactivation of either rNa<sub>V</sub>1.4 or hNa<sub>V</sub>1.5 (Fig.Â <xref rid="Fig4" ref-type="fig">4a</xref>).</p>
        <p>Spider venom peptides similar to Pre1a have been shown to target Na<sub>V</sub>1.1 and Na<sub>V</sub>1.6<sup><xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR28">28</xref></sup>, thus we assessed the activity of Pre1a on hNa<sub>V</sub>1.1 and hNa<sub>V</sub>1.6 stably expressed in HEK cells using the Qpatch16 automated patch-clamp platform (Fig.Â <xref rid="Fig4" ref-type="fig">4e</xref>). To compare possible discrepancies in potency between the two different systems, HEK-hNa<sub>V</sub>1.7 cells were tested in parallel. Pre1a inhibited hNa<sub>V</sub>1.1, hNa<sub>V</sub>1.6, and hNa<sub>V</sub>1.7 with IC<sub>50</sub>s of 57.1ânM (pIC<sub>50</sub> 7.24âÂ±â0.07), 221.6ânM (pIC<sub>50</sub> 6.65âÂ±â0.06), and 15.0ânM (pIC<sub>50</sub> 7.82âÂ±â0.04), respectively (Fig.Â <xref rid="Fig4" ref-type="fig">4f</xref>). An approximate 7-fold increase in potency was determined for the inhibition of hNa<sub>V</sub>1.7 peak current as analysed on the QPatch as compared to the IC<sub>50</sub> obtained for this channel in oocytes. A difference in potency of some molecules or with some receptors is not uncommon when comparing two-electrode voltage clamp of oocytes to data obtained using whole-cell patch clamping of mammalian cells<sup><xref ref-type="bibr" rid="CR37">37</xref>â<xref ref-type="bibr" rid="CR39">39</xref></sup>.</p>
        <p>In addition to the effect of Pre1a on Na<sub>V</sub>1.1 peak current, it also equipotently inhibited Na<sub>V</sub>1.1 fast inactivation with an EC<sub>50</sub> of 41.4ânM (pEC<sub>50</sub> 7.38âÂ±â0.51) (Fig.Â <xref rid="Fig4" ref-type="fig">4g</xref>). Beyond 1âÂµM, inhibition of peak current prevented the analysis of inactivation as the current was fully inhibited. Concentrations up to 1âÎ¼M Pre1a on hNa<sub>V</sub>1.6 or up to 300ânM on hNa<sub>V</sub>1.7 had no effect on inactivation (Fig.Â <xref rid="Fig4" ref-type="fig">4g</xref>). Together, these results demonstrate that Pre1a has a strong preference for modulating neuronal Na<sub>V</sub> channel isoforms over the skeletal muscle (Na<sub>V</sub>1.4) and the cardiac (Na<sub>V</sub>1.5) isoforms. Using the IC<sub>50</sub> for inhibition of Na<sub>V</sub>1.7 peak current as a reference point (to allow comparison across platforms) results in a relative rank order potency for Na<sub>V</sub> modulation of rNa<sub>V</sub>1.3<sub>inact</sub> (0.4)â&gt;âhNa<sub>V</sub>1.7<sub>act</sub> (1)â&gt;ârNa<sub>V</sub>1.2<sub>act</sub> (1.7)â&gt;âhNa<sub>V</sub>1.1<sub>inact</sub> (2.7)â&gt;âhNa<sub>V</sub>1.1<sub>act</sub> (3.8)â&gt;âhNa<sub>V</sub>1.6<sub>act</sub> (15)â&gt;ârNa<sub>V</sub>1.3<sub>act</sub> (70). Thus the effect of Pre1a on Na<sub>V</sub>1.3 inactivation has the highest relative potency for all Na<sub>V</sub> activity (peak current or inactivation) on the channels tested.</p>
      </sec>
      <sec id="Sec6">
        <title>Pre1a modulates Na<sub>V</sub> channel function by inhibiting channel gating</title>
        <p>The mechanism of action of Pre1a was studied by determining the voltage of half maximal effect (<italic>V</italic>
<sub><italic>1/2</italic></sub>) of channel gating for rNa<sub>V</sub>1.2, rNa<sub>V</sub>1.3 and hNa<sub>V</sub>1.7 expressed in oocytes (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>). Pre1a (1âÂµM) significantly shifted the <italic>V</italic>
<sub><italic>1/2</italic></sub> of rNa<sub>V</sub>1.2 and hNa<sub>V</sub>1.7 activation by +14.9âmV and +13.8âmV, respectively (Fig.Â <xref rid="Fig5" ref-type="fig">5a</xref>), whilst having no effect on the <italic>V</italic>
<sub><italic>1/2</italic></sub> of activation of rNa<sub>V</sub>1.3 peak current (Fig.Â <xref rid="Fig5" ref-type="fig">5b</xref>). Pre1a had no effect on the <italic>V</italic>
<sub><italic>1/2</italic></sub> of inactivation of rNa<sub>V</sub>1.2 or hNa<sub>V</sub>1.7 (Fig.Â <xref rid="Fig5" ref-type="fig">5a</xref>) or rNa<sub>V</sub>1.3, however, it did prevent the current of Na<sub>V</sub>1.3 from fully inactivating (Fig.Â <xref rid="Fig5" ref-type="fig">5b</xref>). In contrast, 1âÎ¼M Pre1a shifted the <italic>V</italic>
<sub><italic>1/2</italic></sub> of activation of the rNa<sub>V</sub>1.3 late current by +9.6âmV (Fig.Â <xref rid="Fig5" ref-type="fig">5c</xref>).<fig id="Fig5"><label>Figure 5</label><caption><p>Pre1a (1âÎ¼M) affects the voltage-dependence of activation of rNa<sub>V</sub>1.2 and hNa<sub>V</sub>1.7 and the steady-state inactivation (SSIN) of rNa<sub>V</sub>1.3. (<bold>a</bold>) 1âÂµM Pre1a causes a depolarizing shift in the <italic>V</italic>
<sub><italic>1/2</italic></sub> of activation of rNa<sub>V</sub>1.2 (control <italic>V</italic>
<sub><italic>1/2</italic></sub>â=ââ19.73âÂ±â0.85; Pre1a <italic>V</italic>
<sub><italic>1/2</italic></sub>â=ââ4.88âÂ±â2.06, nâ=â5) and hNa<sub>V</sub>1.7 (control <italic>V</italic>
<sub><italic>1/2</italic></sub>â=ââ22.19âÂ±â0.01, Pre1a <italic>V</italic>
<sub><italic>1/2</italic></sub>â=ââ8.37âÂ±â0.02, nâ=â6). 1âÂµM Pre1a had no significant effect on <italic>V</italic>
<sub><italic>1/2</italic></sub> inactivation of rNa<sub>V</sub>1.2 (control <italic>V</italic>
<sub><italic>1/2</italic></sub>â=ââ45.23âÂ±â0.37; Pre1a <italic>V</italic>
<sub><italic>1/2</italic></sub>â=ââ47.92âÂ±â0.58) and hNa<sub>V</sub>1.7 (control <italic>V</italic>
<sub><italic>1/2</italic></sub>â=ââ38.42âÂ±â0.61; Pre1a <italic>V</italic>
<sub><italic>1/2</italic></sub>â=ââ39.97âÂ±â0.82). (<bold>b</bold>) Voltage-dependence of activation and SSIN of rNa<sub>V</sub>1.3 in the absence and presence of 1âÂµM Pre1a (nâ=â11). Pre1a had no significant effect on voltage-dependence of peak current activation (control <italic>V</italic>
<sub><italic>1/2</italic></sub>â=ââ15.13âÂ±â0.65; Pre1a <italic>V</italic>
<sub><italic>1/2</italic></sub>â=ââ14.23âÂ±â0.52), or SSIN (control <italic>V</italic>
<sub><italic>1/2</italic></sub>â=ââ18.41âÂ±â0.52; Pre1a <italic>V</italic>
<sub><italic>1/2</italic></sub>â=ââ19.8âÂ±â1.26), other than preventing the current from fully inactivating at positive potentials. (<bold>c</bold>) Pre1a (1âÎ¼M) caused a strong positive shift in the voltage-dependence of activation for rNa<sub>V</sub>1.3 late current (analysed at 100âms) (control <italic>V</italic>
<sub><italic>1/2</italic></sub>â=ââ20.64âÂ±â0.54; Pre1a <italic>V</italic>
<sub><italic>1/2</italic></sub>â=ââ11.14âÂ±â0.58).</p></caption><graphic xlink:href="41598_2017_1129_Fig5_HTML" id="d29e1699"/></fig>
</p>
        <p>Depolarising shifts in the activation of rNa<sub>V</sub>1.2 and hNa<sub>V</sub>1.7 and of the rNa<sub>V</sub>1.3 late current are consistent with inhibition of channel gating via interactions with the voltage-sensing domains of repeat II and IV, respectively. Therefore, Pre1a is clearly a gating modifier that interacts with Na<sub>V</sub> channels in a subtype-dependent manner. As Pre1a inhibits both Na<sub>V</sub> channel activation and fast inactivation, we propose using the prefix Î²/Î´ according to the proposed nomenclature for spider venom peptides<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>.</p>
      </sec>
      <sec id="Sec7">
        <title>Pre1a interacts with the S3-S4 linkers of hNa<sub>V</sub>1.7 DII and DIV</title>
        <p>The extracellular S3-S4 linker region has been demonstrated to play a key role as a binding determinant for spider venom peptides to voltage-sensing domains<sup><xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR40">40</xref></sup>. Given that Pre1a potently affects the activation of hNa<sub>V</sub>1.7, we wanted to determine if this inhibition was mediated via interactions with a specific voltage-sensor domain. To this end, we used the approach of Bosmans <italic>et al</italic>., whereby the S3-S4 linker region of the K<sub>V</sub>2.1 channel was substituted with corresponding linker region of hNa<sub>V</sub>1.7 DI to DIV<sup><xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR41">41</xref></sup>. The effect of Pre1a on the resultant K<sup>+</sup> current was then tested for native K<sub>V</sub>2.1 and each of the domain chimaeras. Pre1a (1âÎ¼M) had no effect on wild-type K<sub>V</sub>2.1 or the DI and DIII chimaeras, however it inhibited outward current carried by the Na<sub>V</sub>1.7 DII and DIV/K<sub>V</sub>2.1 chimaeras by 44.0âÂ±â4.6% and 27.1âÂ±â3.8% (nâ=â6), respectively (Fig.Â <xref rid="Fig6" ref-type="fig">6a and b</xref>). Several of the residues crucial for the interaction of HwTxIV with the DII S3-S4 region of Na<sub>V</sub>1.7 as determine by Xiao <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> are also present in DIV, but not in the S3-S4 linker of Na<sub>V</sub>1.7 DI, DIII or Kv2.1 (Fig.Â <xref rid="Fig6" ref-type="fig">6c</xref>), which supports our observation of weaker effect of Pre1a on the DIV chimaera than the DII chimaera. Interaction with DII is completely consistent with Pre1aâs inhibition of Na<sub>V</sub>1.7 activation. Interestingly, the interaction with the Na<sub>V</sub>1.7 DIV/K<sub>V</sub>2.1 chimaera suggests that Pre1a should have an effect on the inactivation of hNa<sub>V</sub>1.7, as was noted for hNa<sub>V</sub>1.1 and rNa<sub>V</sub>1.3. However, we observed no effects of Pre1a on the inactivation of Na<sub>V</sub>1.7 at up to 1âÎ¼M in oocytes or 300ânM in HEK cells. These results suggest that an interaction with the S3-S4 linker alone is not sufficient to result in a potent functional effect on DIV, consistent with the effects of the spider peptide Î´-Hm1a on Na<sub>V</sub>1.1<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.<fig id="Fig6"><label>Figure 6</label><caption><p>Pre1a can interact with the DII and DIV S3-S4 linker of hNa<sub>V</sub>1.7. <bold>(a)</bold> Representative traces showing the effect of Pre1a (1âÂµM) on K<sub>V</sub>2.1 and chimaeras of K<sub>V</sub>2.1 containing S3-S4 linker region from each domain of hNa<sub>V</sub>1.7. <bold>(b)</bold> Normalised peak-current inhibition by Pre1a (1âÂµM) for each K<sub>V</sub>2.1/hNa<sub>V</sub>1.7 chimaera (nâ=â6). Chimaeras of K<sub>V</sub>2.1 with the hNa<sub>V</sub>1.7 DII and DIV had peak current inhibited after addition of 1âÂµM Pre1a by 44.0âÂ±â4.6% and 27.1âÂ±â3.8%, respectively. <bold>(c)</bold> Alignment of K<sub>V</sub>2.1/Na<sub>V</sub>1.7 chimaera S3-S4 regions. Grey highlight indicates the residues determined by Xiao <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> to be key for HwTxIV functional effects on hNa<sub>V</sub>1.7.</p></caption><graphic xlink:href="41598_2017_1129_Fig6_HTML" id="d29e1882"/></fig>
</p>
      </sec>
      <sec id="Sec8">
        <title>Pre1a requires interactions with S3-S4 and S1-S2 regions to produce a functional effect at DIV</title>
        <p>The results above show that Pre1a has potent and subtype-dependent effect on Na<sub>V</sub> channel gating. It potently inhibits the activation (DII effect) of hNa<sub>V</sub>1.1, rNa<sub>V</sub>1.7 and rNa<sub>V</sub>1.2, but not rNa<sub>V</sub>1.3, whereas it selectively inhibits the inactivation (DIV effect) of Na<sub>V</sub>1.1 and 1.3, but not 1.2 or 1.7. The striking differences in effects on Na<sub>V</sub>1.1, 1.2 and 1.3 are of particular significance for understanding the molecular basis of Pre1aâs subtype selectivity as these three channels have essentially identical S3-S4 linker regions in both DII and DIV (Fig.Â <xref rid="Fig7" ref-type="fig">7a</xref>) (note that Na<sub>V</sub>1.1 DII S3-S4 has an M to V substitution at the top of the S3 helix). Thus, this region cannot account for the substantial differences in Na<sub>V</sub> channel subtype selectivity observed for Pre1a. The S1-S2 linker region has previously been shown to contribute to the interaction of HwTxIV with Na<sub>V</sub>1.7 via E753 a the top of S1<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. This residue is highly conserved in all Na<sub>V</sub> channels, thus it cannot account for the subtype selectivity that we observed. FigureÂ <xref rid="Fig7" ref-type="fig">7a</xref> shows that there is sufficient sequence variation between Na<sub>V</sub>1.1, 1.2, 1.7 and 1.3 in the first half of S2 of DIV (indicated as 1, 2 and 3) to possibly explain our data. Previous mutagenesis studies on DII<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> and DIV<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> have shown that the divergent residues in region 1 have little effect on the activity of HwTxIV and Î´-Hm1a, respectively. As region 3 of helix S2 is identical in both Na<sub>V</sub>1.1 and Na<sub>V</sub>1.3, but not 1.2 and 1.7, we assessed the potential role of these two residues (Ser/Arg) in the ability of Pre1a to inhibit inactivation. Using a chimaera-based approach we found that replacing the S3-S4 linker of rNa<sub>V</sub>1.4 (Pre1a insensitive) with corresponding linker from hNa<sub>V</sub>1.1 (Pre1a sensitive) was not sufficient to allow inhibition of inactivation by Pre1a (1âÎ¼M) (Fig.Â <xref rid="Fig7" ref-type="fig">7b,c and d</xref>). Using the rNa<sub>V</sub>1.4<sub>(1.1:S3-S4)</sub> background, introduction of Ser1379 (S1574 in hNa<sub>V</sub>1.1), but not Arg1380 from Na<sub>V</sub>1.1 S1-S2 was sufficient for Pre1a to have a functional effect on both the extent (Fig.Â <xref rid="Fig7" ref-type="fig">7c</xref>) and rate (Fig.Â <xref rid="Fig7" ref-type="fig">7d</xref>) of fast inactivation.<fig id="Fig7"><label>Figure 7</label><caption><p>The S3-S4 linker alone accounts for the subtype selectivity of Pre1a. (<bold>a</bold>) Alignment of DII and DIV extracellular linkers S1-S2 and S3-S4 for Na<sub>V</sub> channel isoforms used in this study. Grey shading indicates identity to rNa<sub>V</sub>1.3 for both domains, residue colouring indicates; <bold>blue</bold>â=âbasic/positive, <bold>red</bold>â=âacidic/negative, <bold>green</bold>â=âpolar, <bold>black</bold>â=âhydrophobic. Helices are defined based on the structures of rabbit Ca<sub>V</sub>1.1 (PDB: 5GJV) for DII, and the Na<sub>V</sub>Ab/hNa<sub>V</sub>1.7 chimaera (PDB: 5EK0) for DIV. *Indicates residues mutated in DII by Xiao <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, red highlight indicates importance for HwTxIV interaction. <bold>(b</bold>) Representative traces showing the effect of 1âÂµM Pre1a on hNa<sub>V</sub>1.1 and chimaeras of rNa<sub>V</sub>1.4 containing the S3-S4 linker region of Nav1.1 DIV, and additional Na<sub>V</sub>1.4 to 1.1 point mutants in the adjacent S1-S2 linker (schematics illustrating the chimaera constructions are shown below the respective current trace). <bold>(c</bold>) Normalised effect of Pre1a on the late current of channels in B (nâ=â5â6). <bold>(d</bold>) Effect of Pre1a (1âÎ¼M) on the Tau of current inactivation (determined from single exponential fit) for channels shown in 7B (nâ=â5â6). <sup>#</sup>Pâ&lt;â0.05 Wilcoxon paired t-test.</p></caption><graphic xlink:href="41598_2017_1129_Fig7_HTML" id="d29e2049"/></fig>
</p>
      </sec>
      <sec id="Sec9">
        <title>Effects of Pre1a on SH-SY5Y human neuroblastoma cells and rat dorsal root ganglion neurons</title>
        <p>As reported previously, Na<sub>V</sub>1.2, Na<sub>V</sub>1.3 and Na<sub>V</sub>1.7 (but not Na<sub>V</sub>1.1 or Na<sub>V</sub>1.6) are robustly expressed in the human neuroblastoma cell line, <italic>SH-SY5Y</italic>
<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. Therefore, synthetic Pre1a was tested on <italic>SH-SY5Y</italic> cells using manual patch clamp to assess the effects on native human Na<sub>V</sub> channel currents. As shown in Fig.Â <xref rid="Fig8" ref-type="fig">8</xref>, 300ânM Pre1a inhibited the rapid peak Na<sup>+</sup> current in a manner consistent with previously observed effects on rNa<sub>V</sub>1.2 and hNa<sub>V</sub>1.7, while concurrently slowing fast inactivation as was observed with rNa<sub>V</sub>1.3. This suggests that endogenously expressed hNa<sub>V</sub>1.3 exhibits similar sensitivity to Pre1a as compared to the rat isoform expressed in oocytes.<fig id="Fig8"><label>Figure 8</label><caption><p>Pre1a inhibits native human and rat Na<sub>V</sub> currents. <bold>(a)</bold> Application of 300ânM sPre1a on the human neuroblastoma cell line, <italic>SH-SY5Y</italic>, inhibits both peak current and fast inactivation, consistent with a Na<sub>V</sub>1.3 and Na<sub>V</sub>1.7 effect. <bold>(b)</bold> sPre1a (300ânM) applied to DRG neurons from sham and nerve injured rats resulted in a similar effect to that seen with <italic>SH-SY5Y</italic> cells. <bold>(c)</bold> Representative traces showing the effect of Pre1a (300ânM) on <italic>SH-SY5Y</italic> cell and DRG neuron from sham animal (controlâ=âblue; 300ânM sPre1aâ=âred).</p></caption><graphic xlink:href="41598_2017_1129_Fig8_HTML" id="d29e2140"/></fig>
</p>
        <p>Additionally, small DRG neurons were excised from both sham and peripheral nerve ligated (PNL) adult rats, 7 days post operation. In both sets of DRG neurons, 300ânM synthetic Pre1a inhibited the peak Na<sup>+</sup> current and slowed fast inactivation in a manner comparable to <italic>SH-SY5Y</italic> cells (Fig.Â <xref rid="Fig8" ref-type="fig">8</xref>). Na<sub>V</sub>1.3 expression is barely detectable in Sprague-Dawley rats at 30 days post-natal<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> and it has beenÂ shown that this channel is upregulated and highly expressed in sensory neurons after 7â9 days post axotomy of peripheral, but not central axons<sup><xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref></sup>. Therefore, minimal effects on fast inactivation of neurons from sham rats were expected, but a substantial effect on the fast inactivation of DRG neurons from post-PNL rats was expected but not observed (Fig.Â <xref rid="Fig8" ref-type="fig">8b</xref>). This result was surprising, as developmental and post-injury regulation of Na<sub>V</sub>1.3 would suggest this channel should not play a significant role in conductance for adult DRG neurons isolated from sham animals. We showed that Pre1a (at ~30ânM) also inhibits fast inactivation of Na<sub>V</sub>1.1 but not Na<sub>V</sub>1.6, thus the persistent current observed with Sham rat DRG neurons in the presence of Pre1a is likely due to effects on Na<sub>V</sub>1.1, which is present in adult neurons and has been reported to not undergo regulatory changes post-axotomy<sup><xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR46">46</xref></sup>.</p>
      </sec>
    </sec>
    <sec id="Sec10" sec-type="discussion">
      <title>Discussion</title>
      <p>We have identified and characterised Î²/Î´-TRTX-Pre1a, a tarantula venom peptide that potently modulates neuronal Na<sub>V</sub> channels and possesses a unique structural and pharmacological profile. Pre1a exhibits over 70% sequence similarity with several other spider venom peptides (e.g. PaurTx3, CcoTx1, GpTx1 and Ccy1b<sup><xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR47">47</xref></sup>); however, the toxin is unique among these peptides in its ability to potently and selectively inhibit fast inactivation of Na<sub>V</sub>1.1 and Na<sub>V</sub>1.3. Furthermore, Pre1a shows a marked structural heterogeneity/flexibility in both aqueous and organic solvents, which may be related to its unique activity profile when compared to its closest sequence relatives. Thus, Pre1a represents a valuable research tool to help determine the molecular basis for spider venom peptide interactions with multiple modulatory sites in sodium channels, particularly in respect to effects on fast inactivation.</p>
      <p>Na<sub>V</sub> channel fast inactivation is controlled by the movement of the DIV voltage-sensing domain<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Although several spider venom peptides (such as JzTxI and JzTxII) have previously been shown to preferentially inhibit Na<sub>V</sub> channel fast inactivation, they are either relatively non-selective<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> or preferentially target Na<sub>V</sub>1.5<sup><xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref></sup>. Two other spider peptides (ProTx-II and JzTxIV) have been found to inhibit both peak current and fast inactivation of Na<sub>V</sub> channels<sup><xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR25">25</xref></sup>, much like Pre1a. However, all these peptides share less than 50% similarity with Pre1a (See Fig.Â <xref rid="Fig1" ref-type="fig">1d</xref>) and have very different subtype selectivity profiles suggesting that Pre1a can help define the basis for subtype selective interactions with DIV. Indeed, through a series of functional experiments using channel chimaeras and point mutants, we demonstrated that a serine residue in the S2 helix of DIV that is unique to hNa<sub>V</sub>1.1 (S1574) and rNa<sub>V</sub>1.3 (S1510) is responsible for the selective modulation of fast inactivation by Pre1a. Our results are consistent with several reports suggesting that this serine residue is a major determinant for the impressively subtype selective effects of both small molecule drugs and another spider venom peptide not related to Pre1a. ICA-121431 inhibits hNa<sub>V</sub>1.3 and hNa<sub>V</sub>1.1 peak current with ~1000-fold selectivity and functions by trapping the DIV VSD in the activated state (stabilising fast inactivation, rather than inhibiting it)<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>, whereas Î´-TRTX-Hm1a (Hm1a) was recently characterised as a selective inhibitor of inactivation of Na<sub>V</sub>1.1<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>, having been previously discovered as a low-affinity K<sub>V</sub>4.2 inhibitor<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. Furthermore, a co-crystal structure of a Na<sub>V</sub>1.7 VSD IV chimaera with the small molecule Na<sub>V</sub> channel inhibitor GX-936 has been solved revealing the detailed molecular interactions responsible for its selectivity<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. GX-936 has the same mechanism of action as ICA-121431 thus arrests the VSD in the inactivated state as opposed to the resting state targeted by Pre1a and Hm1a. Remarkably, and despite the different state stabilised by these peptides and small molecules, they all rely on the same region in S2 (S1574 in hNa<sub>V</sub>1.1 and neighbouring residues) for their functional selectivity. Together, these results illustrate that the S2 helix is an important locus for subtype selective modulation of Na<sub>V</sub> channel fast inactivation and that the key residues involved appear to be accessible to ligands in both the resting and inactivated states.</p>
      <p>Although Hm1a and Pre1a share the ability to inhibit Na<sub>V</sub>1.1 fast inactivation, they differ greatly in primary sequence (only 17% similarity when excluding the structurally critical Cys residues). Interestingly, the small amount of similarity that does exist between them is a hydrophobic patch clustered in loop 1 of the peptide (Fig.Â <xref rid="Fig1" ref-type="fig">1d</xref>). Co-incidentally this is the region of Pre1a that is structurally mobile, a characteristic that has not been reported for venom peptides most closely related to Pre1a and that seem to predominantly inhibit channel activation<sup><xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR47">47</xref></sup>. From extensive structure-activity studies carried out by several pharmaceutical companies on spider venom peptides closely related to Pre1a (i.e. GpTx1, CcoTx1 and HwTxIV<sup><xref ref-type="bibr" rid="CR26">26</xref>â<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR34">34</xref></sup>), the aromatic residues at the tip of Loop 1 are key residues for the interaction of these peptides with Na<sub>V</sub> channels, in particular for their inhibitory effects on channel activation. Whether the flexibility of loop 1 in Pre1a has any role in its ability to potently interact with both DII and/or DIV VSDs (i.e., resulting in two conformations of the same pharmacophore residues) remains to be elucidated.</p>
      <p>The interactions of spider venom peptides that inhibit Na<sub>V</sub> channel activation have been the focus of extensive chimaera and scanning mutagenesis studies to characterise the binding site on the channel. Bosmans <italic>et al</italic>. demonstrated that the S3-S4 linker region of any of DI to DIII can be a primary binding determinant for a number of venom peptides by transplanting this region in to a toxin insensitive background and transferring functional peptide binding<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. Subsequently, a motif, which spans the DII S1-S2 <italic>and</italic> S3-S4 regions, that is critical for the inhibitory activity of HwTx-IV on hNa<sub>V</sub>1.7 was identified and consists of the residues E753 in S1, and E811, L814, D816, E818 in S3-S4<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> (See red asterisks in Fig.Â <xref rid="Fig7" ref-type="fig">7a</xref>). This has since been functionally demonstrated for two other spider peptides with substantial similarity to Pre1a<sup><xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref></sup> as well as suggested structurally (in solution using NMR) for the interaction of VSTX1 and the VSD of K<sub>V</sub>Ap<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Our data showing a greater effect of Pre1a on the DII Kv2.1/hNav1.7 S3-S4 chimaera than that containing the DIV S3-S4 linker is in accord with the these previous studies. However, interaction with the residues identified in S1 and S3-S4 does not explain the substantial differences in Pre1aâs ability to inhibit Na<sub>V</sub> channel activation and despite the studies carried out to date, little insight into the basis of Na<sub>V</sub> channel subtype selectivity has been gained in regards to DII. Pre1a most potently inhibited the activation of Na<sub>V</sub>1.7 and Na<sub>V</sub>1.2 with ~70-fold selectivity over Na<sub>V</sub>1.3. The latter two channels have identical sequences in the S3-S4 linker, thus binding to this region cannot account for the observed selectivity. Interestingly hNa<sub>V</sub>1.1 and rNa<sub>V</sub>1.2 only differ by only two residues in the S2 helix, a conservative Thr (1.3) to Ser (1.2) substitution (at the position corresponding to the Ser1574 in Nav1.1 DIV) and a less conservative Gln (1.3) to Glu (1.2) substitution at the top of S2. This strongly suggests that residues in one or both of these positions make major contributions to the interaction of Pre1a with Na<sub>V</sub> VSD (driven primarily by interactions with S3-S4) that together result in functional inhibition of the channel. Thus, similar to what we showed for the molecular basis of sub-type selective inhibition of inactivation, subtype selective interactions at DII are also likely determined by the variability in the S2 helix.</p>
      <p>In conclusion, we have identified a novel spider venom peptide and demonstrated how its so far unique activity on the Na<sub>V</sub> channel family can be used to gain insight into the molecular basis of subtype selectivity. It should be noted that few venom peptide modulators of Na<sub>V</sub> channels have been studied in the same detail as reported here, thus the structural heterogeneity and binding site promiscuity of Pre1a may indeed be a more common property than we realise. Pre1a has great value as a research tool for exploration of the selectivity profile of activation and inactivation on different Na<sub>V</sub> channel isoforms, as well as exploring the consequences and effects of conformational flexibility to activity in this family of channel modulators.</p>
    </sec>
    <sec id="Sec11" sec-type="materials|methods">
      <title>Methods</title>
      <sec id="Sec12">
        <title>Venom peptide purification</title>
        <p>
<italic>Psalmopoeus reduncus</italic> venom was purchased from SpiderPharm (Yarnell). Venom was fractionated using a C18 218TP54 column (4.6âÃâ250âmm, 5âÎ¼m, Grace Discovery Sciences) with solvent A (H<sub>2</sub>O, 0.05% TFA) and B (90% acetonitrile, 0.045% TFA) over a gradient of solvents (15â40% B in 36âmin, 40â100% B in 12.5âmin at 1âml/min). Fractions were collected, dried and assayed for activity against hNa<sub>V</sub>1.7 expressed in <italic>Xenopus laevis</italic> oocytes. The active fractions were further separated on a PromixMP column (4.6âÃâ250âmm, Sielc) with a gradient of 10â35% B in 35âmin at 1âml/min, then a Prosphere C4 column (3.0âÃâ150âmm, Grace Discovery Sciences) with a gradient of 20â45% B at 0.75âml/min.</p>
        <p>Peptides were analysed using MALDI-TOF mass spectrometry (Applied Biosystems 4700 Proteomics Bioanalyser) in reflector mode using Î±-cyano-4-hydroxy-cinnamic acid (CHCA, 5âmg/ml in 60:40 solvent B:A). Reduction/alkylation and sequencing of approximately 3âÎ¼g of the peptide was carried out by N-terminal Edman degradation.</p>
      </sec>
      <sec id="Sec13">
        <title>Peptide synthesis</title>
        <p>Synthetic Pre1a was assembled manually using Boc SPPS chemistry as described previously<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. The side-chain protecting groups chosen were Asn (Xan), Arg (Tos), Asp (OcHex), Cys (4-MeBzl), Lys (ClZ), Ser (Bzl), Trp (CHO) and Tyr (BrZ). The crude reduced peptide was purified using preparative reversed-phase chromatography (Vydac C18 218TP1022), using a gradient of 0â80% B over 80âmin). The peptide was oxidised at a concentration of 0.02âmM in either aqueous 0.33âM NH<sub>4</sub>OAc/0.5âM GnHCI or 2âM NH<sub>4</sub>OH/0.1âM NH<sub>4</sub>OAc at pH 7.8, 4âÂ°C in the presence of both reduced and oxidised glutathione (peptide:GSH:GSSG, 1:100:10, molar ratio). Oxidised peptides were purified using preparative RP-HPLC.</p>
      </sec>
      <sec id="Sec14">
        <title>Bacterial recombinant production of Pre1a</title>
        <p>Pre1a was produced recombinantly using an <italic>E. coli</italic> periplasmic expression system as described previously<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. Briefly, a synthetic gene encoding Pre1a was codon optimised for bacterial expression and subcloned into a pLicC-His<sub>6</sub>-MBP periplasmic expression vector, where the peptide is expressed as a C-terminal fusion to His<sub>6</sub>-tagged maltose binding protein (MBP) separated by a tobacco etch virus (TEV) protease cleavage site, leaving an additional N-terminal <italic>Ser</italic> after cleavage. Fusion proteins were expressed in <italic>E. coli</italic> strain BL21(Î»DE3) and isolated from cell lysates using Ni-NTA Superflow resin (Qiagen). The His<sub>6</sub>-MBP tag was removed from the fusion protein using TEV protease, and recombinant Pre1a purified using RP-HPLC.</p>
        <p>For production of uniformly <sup>13</sup>C/<sup>15</sup>N-labelled Pre1a, cultures were grown in minimal medium supplemented with <sup>13</sup>C<sub>6</sub>-glucose and <sup>15</sup>NH<sub>4</sub>Cl as the sole carbon and nitrogen sources, respectively. In order to facilitate comparisons between synthetic and recombinant Pre1a, residue numbers for the native toxin are used throughout the text even though the recombinant toxin contains an additional N-terminal serine residue that is a vestige of the TEV cleavage site.</p>
      </sec>
      <sec id="Sec15">
        <title>Two-electrode voltage clamp analysis on Na<sub>V</sub> channel-expressing oocytes</title>
        <p>The preparation and injection of <italic>Xenopus laevis</italic> oocytes and Na<sub>V</sub> channel recordings using two-electrode voltage-clamp (TEVC) were carried out as described previously<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. Capped cRNA encoding rat Na<sub>V</sub>1.2, Na<sub>V</sub>1.3 and Na<sub>V</sub>1.4, and human Na<sub>V</sub>1.5 and Na<sub>V</sub>1.7 were injected at 20â40 ng of cRNA/oocyte and kept at 17â18âÂ°C in ND96 solution containing (in mM) 96 NaCl, 2 KCl, 1 CaCl<sub>2</sub>, 2 MgCl<sub>2</sub>, 5 HEPES, 5 pyruvic acid, 50âÂµg/ml gentamicin (pH 7.4), and horse serum (2.5%). Membrane currents were recorded 2â5 days after injection. Oocytes were clamped at â90âmV and currents were elicited by a 50âms depolarising step to â10 or 0âmV every 10âs for concentration response curves. Both peak and late current (50âms post peak) were analysed. The concentration response curves were fitted to the Hill equation (GraphPad Prism 6). Current-voltage (<italic>I-V</italic>) relationships and voltage-dependence of fast inactivation were determined using a family of 100âms conditioning pulses from â100âmV to +50âmV (+60âmV for rNa<sub>V</sub>1.3) in 5âmV steps, followed by a test depolarisation step to 0âmV with a 20âs sweep interval from a holding potential of â90âmV. To determine the voltage-dependence of activation non-normalised peak current was used from the <italic>I-V</italic> family to calculate channel conductance using the equation: <italic>G</italic>(<italic>V</italic>)â=â<italic>I</italic>/(<italic>V</italic> â <italic>V</italic>
<sub><italic>rev</italic></sub>), in which <italic>I</italic>, <italic>V</italic>, and <italic>V</italic>
<sub><italic>rev</italic></sub> represent inward Na<sub>V</sub> current, test potential, and reversal potential, respectively. The half-activation potential (<italic>V</italic>
<sub><italic>1/2</italic></sub>) was determined using a Boltzmann fit (GraphPad Prism 6). All data points are shown as the pIC<sub>50</sub>âÂ±âS.E.M., as well as the IC<sub>50</sub>. Replicates (<italic>n</italic>) represent separate experimental oocytes. Pre1a was resuspended in ND96 solution containing 0.1% bovine serum albumin for all activity analysis. Construction and recording of the K<sub>V</sub>2.1chimaeras containing hNa<sub>V</sub>1.7 DI-DIV S3-S4 linker regions was completed as described previously<sup><xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR41">41</xref></sup>. Design and construction of the hNa<sub>V</sub>1.1/rNa<sub>V</sub>1.4 DIV chimaeras is detailed in Osteen <italic>et al</italic>.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Not all isoforms of Na<sub>V</sub>s from the same organism were available at the time of experimentation. Even though different species (rat and human) were used, careful analysis of the data in relation to the sequence differences of the isoforms used, still yields valuable insights in to the molecular basis of peptide:channel interaction.</p>
      </sec>
      <sec id="Sec16">
        <title>NMR data acquisition and structural analysis</title>
        <p>
<sup>13</sup>C/<sup>15</sup>N-labelled peptide in 20âmM potassium phosphate buffer, pH 5 containing 5% D<sub>2</sub>O was filtered using a low-protein-binding Ultrafree-MC centrifugal filter (0.22âÂµm pore size; Millipore, MA, USA), then 300âÎ¼L of ~300âÎ¼M was added to a susceptibility-matched 5âmm outer-diameter microtube (Shigemi Inc.). NMR spectra were acquired at 298âK on a 900âMHz Bruker AVANCE II+ spectrometer (Bruker BioSpin) equipped with a cryogenically cooled probe. Data used for resonance assignment were acquired using non-uniform sampling (NUS); sampling schedules that approximated the rate of signal decay along the various indirect dimensions were generated using sched3D<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. The decay rates used were 1âHz for all constant-time <sup>15</sup>N dimensions, 30âHz for all <sup>13</sup>C dimensions, and 15âHz for the semi-constant indirect <sup>1</sup>H dimension of the H(CC) (CO)NH/(H)CC(CO)NH-TOCSY experiments. <sup>13</sup>C- and <sup>15</sup>N-edited HSQC-NOESY experiments were acquired using linear sampling. Separate experiments were acquired for the aliphatic and aromatic regions of the <sup>13</sup>C dimension.</p>
        <p>NUS data were processed using the Rowland NMR toolkit (www.rowland.org/rnmrtk/toolkit.html); maximum entropy parameters were selected automatically as described<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. NMR spectra were analysed and assigned using the program XEASY<sup><xref ref-type="bibr" rid="CR61">61</xref></sup> or SPARKY<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>. <sup>1</sup>H<sub>N</sub>, <sup>15</sup>N, <sup>13</sup>C<sub>Î±</sub>, <sup>13</sup>C<sub>Î²</sub>, and <sup>13</sup>Câ² resonance assignments were obtained from analysis of amide-proton strips in 3D HNCACB, CBCA(CO)NH, and HNCO spectra. Side-chain <sup>1</sup>H and <sup>13</sup>C chemical shifts were obtained primarily from 3D H(CC) (CO)NH-TOCSY and (H)CC(CO)NH-TOCSY spectra, respectively. The remaining side-chain assignments were derived from 3D <sup>15</sup>N- and <sup>13</sup>C-edited NOESY-HSQC spectra. The program TALOS+â<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> was used to predict the secondary structure of the peptide. Disulfide connectives were determined from NOESY patterns<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. During the automated NOESY assignment/structure calculation process, CYANA assigned 90.1% of all NOESY cross-peaks (829 of 920).</p>
      </sec>
      <sec id="Sec17">
        <title>Automated patch clamp analyses on Na<sub>V</sub> channel-expressing mammalian cells</title>
        <p>For patch clamp analysis, HEK293 cells stably co-expressing the hNa<sub>V</sub>1.1, hNa<sub>V</sub>1.6, or hNa<sub>V</sub>1.7 Î±-subunit with the Na<sub>V</sub>Î²<sub>1</sub>-subunit (SB Drug Discovery) were cultured following manufacturer guidelines. Cells were removed from culture at 70% confluency using Detachin (Genlantis) and resuspended to 5âÃâ10<sup>6</sup> cells/mL in Ex-Cell ACF CHO Medium (Life Technologies) supplemented with 25âmM HEPES (Sigma-Aldrich) and 1âÃâGlutamax (Life Technologies) before being transferred to the Q-Patch <italic>Q</italic>-<italic>Stirrer</italic> and allowed to recover for 30âmin before assay.</p>
        <p>The external solution contained (in mM): 140 NaCl, 4 KCl, 2 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 HEPES, 20 TEA-Cl, 10 glucose, pH 7.4 (with NaOH) and adjusted to 315âmOsm 0.05% BSA was added to prevent adsorptive loss of peptide. The intracellular solution contained (in mM): 140 CsF, 1/5 EGTA/CsOH, 10 HEPES and 10 NaCl, pH 7.4 (with CsOH) and adjusted to 320âmOsm. Whole-cell patch-clamp experiments were performed at room temperature on a QPatch-16 automated electrophysiology platform (Biolin Scientific) using 16-channel planar patch chip plates (<italic>Q-Plates</italic>) with a patch hole diameter of 1âÂµm and resistance of 2âÂ±â0.1âMâ¦. Cell positioning and sealing parameters were set as follows: positioning pressure â60 mbar, minimum seal resistance 0.1 GÎ©, holding potential â90âmV and holding pressure â20 mbar. Whole-cell currents were filtered at 5âkHz (8-pole Bessel) and digitised at 25âkHz. A <italic>P/6</italic> online leak-subtraction protocol was used with non-leak-subtracted currents acquired in parallel. Cells were maintained with holding potentials of â80 (hNa<sub>V</sub>1.1) or â100âmV (hNa<sub>V</sub>1.6 and hNa<sub>V</sub>1.7) between protocols, respectively and depolarised to â10âmV with a sweep interval of 20âs to allow complete recovery from inactivation between sweeps. Pre1a concentrations were incubated for a fixed time of 5â10âmin to allow steady-state activity, monitored by the <italic>I-T</italic> plot.</p>
      </sec>
      <sec id="Sec18">
        <title>Patch clamp analyses of SH-SY5Y cells and rat DRG neurons</title>
        <p>Whole-cell patch clamp electrophysiology was carried out on <italic>SH-SY5Y</italic> cells as described previously<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> or from small (&lt;25âÎ¼m diameter) acutely isolated adult male rat DRG neurons as described previously<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. DRG neurons were taken from rats that had undergone either partial ligation of the left sciatic nerve (PNL) to induce a state of neuropathic pain (defined as development of significant mechanical allodynia seven days after surgery) or sham operated rats<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>. <italic>SH-SY5Y</italic> cells were used within 24â72âh, and DRG neurons were used within 6âhours of plating. Only cells with minimal or no processes were used. Whole-cell patch-clamp recordings were performed at room temperature with fire-polished patch electrodes prepared from borosilicate glass (SDR Clinical Technology). Electrode resistance was 3.5â5âMÎ© when filled with an internal solution containing (composition in mM): 120 CsCl, 5 MgATP, 5 NaCl, 2 CaCl<sub>2</sub>, 20 HEPES, 10 EGTA, pH 7.3 and adjusted to 283â286âmOsm. Cells were continuously bathed in a HEPES-buffered physiological saline (HBS; composition in mM): 155 NaCl, 2.5 KCl, 1.8 CaCl<sub>2</sub>, 1.2 MgCl<sub>2</sub>, 10 HEPES, 10 glucose, pH 7.4 (adjusted with NaOH) and adjusted to 328â331âmOsm. Currents were recorded using a HEKA EPC-9 amplifier and PULSE software (v8.8, HEKA Elektronik, Lambrecht/Pfalz, Germany). Data was filtered at 4âkHz and sampled at 20âkHz. Series resistance was compensated by 80%. Capacitance transients were compensated and leak subtraction was performed with a <italic>P/8</italic> online protocol. Drugs were applied to cells using a gravity-fed superfusion system (250âÎ¼m diameter) positioned directly above the cell resulting in rapid solution exchange (&lt;500âms).</p>
      </sec>
      <sec id="Sec19">
        <title>Ethics statement</title>
        <p>All animal experiments complied with the Australian code of practice for the care and use of animals for scientific purposes, (8<sup>th</sup> Ed. 2013) and great care was taken to minimise animal suffering at all times. Experiments involving rats were approved by the University of Sydney (Approval number K00/1-2009/3/4940) or Royal North Shore Hospital/University of Technology Animal Ethics Committee (Approval number 0411-067A). Experiments using <italic>X. laevis</italic> were approved by The University of Queensland Animal Ethics Committee (Approval Number: QBI/059/13/ARC/NHMRC). Oocytes were obtained via recovery surgery performed under tricaine methanesulfonate (MS-222) anaesthesia (animals bathed in 1.3âmg/ml solution). Minimum time between surgeries on the same animal was six months.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Electronic supplementary material</title>
      <sec id="Sec20">
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2017_1129_MOESM1_ESM.pdf"><caption><p>Supplementary data</p></caption></media></supplementary-material>
</p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Electronic supplementary material</bold>
        </p>
        <p>
<bold>Supplementary information</bold> accompanies this paper at doi:10.1038/s41598-017-01129-0
</p>
      </fn>
      <fn>
        <p>
<bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank A. Goldin (University of California) for the rNav1.2 and rNav1.3 clones, and R. Kass (Columbia University) for the hNav1.5 clone. This work was supported by the National Health and Medical Research Council of Australia (NHMRC: APP1067940 to L.D.R.; Program Grant 569927 to R.J.L., P.F.A., M.J.C., D.J.A.), the Australian Research Council (Future Fellowship FT110100925 to M.M.), a Ruth Kirschstein NIH predoctoral fellowship (F31NS084646 to J.G.) and the National Institutes of Health (R01NS091352 to F.B.).</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author Contributions</title>
      <p>Discovery &amp; sequence characterisation (L.D.R.); Synthesis/folding (C.A.U., T.D., P.F.A.); Recombinant production (J.S.W., L.D.R., M.M.); Structural heterogeneity (C.A.U., J.S.W.); NMR studies (Y.C., M.M., L.D.R., J.S.W.); Oocyte assays (J.S.W., L.D.R., B.C.-A., J.G., F.B., D.J.A.); QPatch assays (J.S.W.); SH-SY5Y cells (C.M., M.J.C.); DRG neurons (S.S.M., C.W.V., M.J.C.). Manuscript writing/editing. All authors. Project conception &amp; oversight (LDR).</p>
    </notes>
    <notes notes-type="COI-statement">
      <sec id="FPar1">
        <title>Competing Interests</title>
        <p>The authors declare that they have no competing interests.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="other">Catterall, W. A., Goldin, A. L. &amp; Waxman, S. G. <italic>Voltage-gated sodium channels, introduction</italic>, http://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=82. (2016).</mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="other">Vetter, I. <italic>et al</italic>. Na<sub>V</sub>1.7 as a pain target - from gene to pharmacology. <italic>Pharmacol. Ther</italic>. In press, doi:10.1016/j.pharmthera.2016.11.015 (2016).</mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gilchrist</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Na<sub>V</sub>1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents</article-title>
          <source>ACS Chem. Biol.</source>
          <year>2014</year>
          <volume>9</volume>
          <fpage>1204</fpage>
          <lpage>1212</lpage>
          <pub-id pub-id-type="doi">10.1021/cb500108p</pub-id>
          <?supplied-pmid 24635129?>
          <pub-id pub-id-type="pmid">24635129</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="other">Wingerd, J. S., Vetter, I. &amp; Lewis, R. J. In <italic>Therapeutic Targets</italic> 63â122 (John Wiley &amp; Sons, Inc., 2012).</mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dib-Hajj</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Waxman</surname>
              <given-names>SG</given-names>
            </name>
          </person-group>
          <article-title>The Na<sub>V</sub>1.7 sodium channel: from molecule to man</article-title>
          <source>Nature Reviews Neuroscience</source>
          <year>2012</year>
          <volume>14</volume>
          <fpage>49</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="doi">10.1038/nrn3404</pub-id>
          <?supplied-pmid 23232607?>
          <pub-id pub-id-type="pmid">23232607</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia</article-title>
          <source>J Med Genet</source>
          <year>2004</year>
          <volume>41</volume>
          <fpage>171</fpage>
          <lpage>174</lpage>
          <pub-id pub-id-type="doi">10.1136/jmg.2003.012153</pub-id>
          <?supplied-pmid 14985375?>
          <pub-id pub-id-type="pmid">14985375</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fertleman</surname>
              <given-names>CR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes</article-title>
          <source>Neuron</source>
          <year>2006</year>
          <volume>52</volume>
          <fpage>767</fpage>
          <lpage>774</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuron.2006.10.006</pub-id>
          <?supplied-pmid 17145499?>
          <pub-id pub-id-type="pmid">17145499</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cox</surname>
              <given-names>JJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An SCN9A channelopathy causes congenital inability to experience pain</article-title>
          <source>Nature</source>
          <year>2006</year>
          <volume>444</volume>
          <fpage>894</fpage>
          <lpage>898</lpage>
          <pub-id pub-id-type="doi">10.1038/nature05413</pub-id>
          <?supplied-pmid 17167479?>
          <pub-id pub-id-type="pmid">17167479</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amaya</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The voltage-gated sodium channel Na<sub>V</sub>1.9 is an effector of peripheral inflammatory pain hypersensitivity</article-title>
          <source>J. Neurosci.</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>12852</fpage>
          <lpage>12860</lpage>
          <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4015-06.2006</pub-id>
          <?supplied-pmid 17167076?>
          <pub-id pub-id-type="pmid">17167076</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hains</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Saab</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Waxman</surname>
              <given-names>SG</given-names>
            </name>
          </person-group>
          <article-title>Changes in electrophysiological properties and sodium channel Na<sub>V</sub>1.3 expression in thalamic neurons after spinal cord injury</article-title>
          <source>Brain</source>
          <year>2005</year>
          <volume>128</volume>
          <fpage>2359</fpage>
          <lpage>2371</lpage>
          <pub-id pub-id-type="doi">10.1093/brain/awh623</pub-id>
          <?supplied-pmid 16109750?>
          <pub-id pub-id-type="pmid">16109750</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>The changes in expression of three subtypes of TTX sensitive sodium channels in sensory neurons after spinal nerve ligation</article-title>
          <source>Brain Res. Mol. Brain Res.</source>
          <year>2001</year>
          <volume>95</volume>
          <fpage>153</fpage>
          <lpage>161</lpage>
          <pub-id pub-id-type="doi">10.1016/S0169-328X(01)00226-1</pub-id>
          <?supplied-pmid 11687287?>
          <pub-id pub-id-type="pmid">11687287</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>DâHooge</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Meert</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Exploring the role of nociceptor-specific sodium channels in pain transmission using Nav1.8 and Nav1.9 knockout mice</article-title>
          <source>Behav. Brain. Res.</source>
          <year>2010</year>
          <volume>208</volume>
          <fpage>149</fpage>
          <lpage>157</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbr.2009.11.023</pub-id>
          <?supplied-pmid 19931571?>
          <pub-id pub-id-type="pmid">19931571</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Osteen</surname>
              <given-names>JD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Selective spider toxins reveal a role for the Nav1.1 channel in mechanical pain</article-title>
          <source>Nature</source>
          <year>2016</year>
          <volume>534</volume>
          <fpage>494</fpage>
          <lpage>499</lpage>
          <pub-id pub-id-type="doi">10.1038/nature17976</pub-id>
          <?supplied-pmid 27281198?>
          <pub-id pub-id-type="pmid">27281198</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vetter</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Venomics: a new paradigm for natural products-based drug discovery</article-title>
          <source>Amino Acids</source>
          <year>2011</year>
          <volume>40</volume>
          <fpage>15</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="doi">10.1007/s00726-010-0516-4</pub-id>
          <?supplied-pmid 20177945?>
          <pub-id pub-id-type="pmid">20177945</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saez</surname>
              <given-names>NJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Spider-Venom Peptides as Therapeutics</article-title>
          <source>Toxins</source>
          <year>2010</year>
          <volume>2</volume>
          <fpage>2851</fpage>
          <lpage>2871</lpage>
          <pub-id pub-id-type="doi">10.3390/toxins2122851</pub-id>
          <?supplied-pmid 22069579?>
          <pub-id pub-id-type="pmid">22069579</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="other">Das, S., Gilchrist, J., Bosmans, F. &amp; Van Petegem, F. Binary architecture of the Na<sub>v</sub>1.2-beta2 signaling complex. <italic>Elife</italic><bold>5</bold>, doi:10.7554/eLife.10960 (2016).</mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahern</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Payandeh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bosmans</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chanda</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>The hitchhikerâs guide to the voltage-gated sodium channel galaxy</article-title>
          <source>The Journal of General Physiology</source>
          <year>2016</year>
          <volume>147</volume>
          <fpage>1</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1085/jgp.201511492</pub-id>
          <?supplied-pmid 26712848?>
          <pub-id pub-id-type="pmid">26712848</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bosmans</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Martin-Eauclaire</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Swartz</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Deconstructing voltage sensor function and pharmacology in sodium channels</article-title>
          <source>Nature</source>
          <year>2008</year>
          <volume>456</volume>
          <fpage>202</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="doi">10.1038/nature07473</pub-id>
          <?supplied-pmid 19005548?>
          <pub-id pub-id-type="pmid">19005548</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Capes</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Goldschen-Ohm</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Arcisio-Miranda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bezanilla</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chanda</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Domain IV voltage-sensor movement is both sufficient and rate limiting for fast inactivation in sodium channels</article-title>
          <source>The Journal of General Physiology</source>
          <year>2013</year>
          <volume>142</volume>
          <fpage>101</fpage>
          <lpage>112</lpage>
          <pub-id pub-id-type="doi">10.1085/jgp.201310998</pub-id>
          <?supplied-pmid 23858005?>
          <pub-id pub-id-type="pmid">23858005</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>JZTX-IV, a unique acidic sodium channel toxin isolated from the spider Chilobrachys jingzhao</article-title>
          <source>Toxicon</source>
          <year>2008</year>
          <volume>52</volume>
          <fpage>871</fpage>
          <lpage>880</lpage>
          <pub-id pub-id-type="doi">10.1016/j.toxicon.2008.08.018</pub-id>
          <?supplied-pmid 18848955?>
          <pub-id pub-id-type="pmid">18848955</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bosmans</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Swartz</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Targeting voltage sensors in sodium channels with spider toxins</article-title>
          <source>Trends in Pharmacological Sciences</source>
          <year>2010</year>
          <volume>31</volume>
          <fpage>175</fpage>
          <lpage>182</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tips.2009.12.007</pub-id>
          <?supplied-pmid 20097434?>
          <pub-id pub-id-type="pmid">20097434</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bosmans</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Four novel tarantula toxins as selective modulators of voltage-gated sodium channel subtypes</article-title>
          <source>Mol Pharmacol</source>
          <year>2006</year>
          <volume>69</volume>
          <fpage>419</fpage>
          <lpage>429</lpage>
          <pub-id pub-id-type="doi">10.1124/mol.105.015941</pub-id>
          <?supplied-pmid 16267209?>
          <pub-id pub-id-type="pmid">16267209</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cummins</surname>
              <given-names>TR</given-names>
            </name>
          </person-group>
          <article-title>Common molecular determinants of tarantula Huwentoxin-IV inhibition of Na<sup>+</sup> channel voltage sensors in domains II and IV</article-title>
          <source>Journal of Biological Chemistry</source>
          <year>2011</year>
          <volume>286</volume>
          <fpage>27301</fpage>
          <lpage>27310</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M111.246876</pub-id>
          <?supplied-pmid 21659528?>
          <pub-id pub-id-type="pmid">21659528</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Corzo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Escoubas</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Pharmacologically active spider peptide toxins</article-title>
          <source>CMLS, Cell. Mol. Life Sci.</source>
          <year>2003</year>
          <volume>60</volume>
          <fpage>2409</fpage>
          <lpage>2426</lpage>
          <pub-id pub-id-type="doi">10.1007/s00018-003-3108-6</pub-id>
          <?supplied-pmid 14625686?>
          <pub-id pub-id-type="pmid">14625686</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Blumenthal</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cummins</surname>
              <given-names>TR</given-names>
            </name>
          </person-group>
          <article-title>The Tarantula Toxins ProTx-II and Huwentoxin-IV Differentially Interact with Human Na<sub>v</sub>1.7 Voltage Sensors to Inhibit Channel Activation and Inactivation</article-title>
          <source>Molecular Pharmacology</source>
          <year>2010</year>
          <volume>78</volume>
          <fpage>1124</fpage>
          <lpage>1134</lpage>
          <pub-id pub-id-type="doi">10.1124/mol.110.066332</pub-id>
          <?supplied-pmid 20855463?>
          <pub-id pub-id-type="pmid">20855463</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murray</surname>
              <given-names>JK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Single Residue Substitutions That Confer Voltage-Gated Sodium Ion Channel Subtype Selectivity in the Na<sub>V</sub>1.7 Inhibitory Peptide GpTx-1</article-title>
          <source>J. Med. Chem.</source>
          <year>2016</year>
          <volume>59</volume>
          <fpage>2704</fpage>
          <lpage>2717</lpage>
          <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01947</pub-id>
          <?supplied-pmid 26890998?>
          <pub-id pub-id-type="pmid">26890998</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Revell</surname>
              <given-names>JD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Potency optimization of Huwentoxin-IV on hNav1.7: A neurotoxin TTX-S sodium-channel antagonist from the venom of the Chinese bird-eating spider Selenocosmia huwena</article-title>
          <source>Peptides</source>
          <year>2013</year>
          <volume>44</volume>
          <fpage>40</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="doi">10.1016/j.peptides.2013.03.011</pub-id>
          <?supplied-pmid 23523779?>
          <pub-id pub-id-type="pmid">23523779</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shcherbatko</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Engineering Highly Potent and Selective Microproteins Against Nav1.7 Sodium Channel for Treatment of Pain</article-title>
          <source>Journal of Biological Chemistry</source>
          <year>2016</year>
          <volume>291</volume>
          <fpage>13974</fpage>
          <lpage>13986</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M116.725978</pub-id>
          <?supplied-pmid 27129258?>
          <pub-id pub-id-type="pmid">27129258</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Gentz</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Escoubas</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>GM</given-names>
            </name>
          </person-group>
          <article-title>A rational nomenclature for naming peptide toxins from spiders and other venomous animals</article-title>
          <source>Toxicon</source>
          <year>2008</year>
          <volume>52</volume>
          <fpage>264</fpage>
          <lpage>276</lpage>
          <pub-id pub-id-type="doi">10.1016/j.toxicon.2008.05.020</pub-id>
          <?supplied-pmid 18619481?>
          <pub-id pub-id-type="pmid">18619481</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <mixed-citation publication-type="other">GÃ¼ntert, P. In <italic>Protein NMR Techniques</italic> Vol. 278 <italic>Methods in Molecular Biologyâ¢</italic> (ed. A. Kristina Downing) Ch. 17, 353â378 (Humana Press, 2004).</mixed-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Delaglio</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cornilescu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bax</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts</article-title>
          <source>Journal of biomolecular NMR</source>
          <year>2009</year>
          <volume>44</volume>
          <fpage>213</fpage>
          <lpage>223</lpage>
          <pub-id pub-id-type="doi">10.1007/s10858-009-9333-z</pub-id>
          <?supplied-pmid 19548092?>
          <pub-id pub-id-type="pmid">19548092</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lau</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Mobli</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Molecular basis of the interaction between gating modifier spider toxins and the voltage sensor of voltage-gated ion channels</article-title>
          <source>Sci. Rep</source>
          <year>2016</year>
          <volume>6</volume>
          <fpage>34333</fpage>
          <pub-id pub-id-type="doi">10.1038/srep34333</pub-id>
          <?supplied-pmid 27677715?>
          <pub-id pub-id-type="pmid">27677715</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klint</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Chin</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Mobli</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Rational Engineering Defines a Molecular Switch That Is Essential for Activity of Spider-Venom Peptides against the Analgesics Target NaV1.7</article-title>
          <source>Mol. Pharmacol.</source>
          <year>2015</year>
          <volume>88</volume>
          <fpage>1002</fpage>
          <lpage>1010</lpage>
          <pub-id pub-id-type="doi">10.1124/mol.115.100784</pub-id>
          <?supplied-pmid 26429937?>
          <pub-id pub-id-type="pmid">26429937</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minassian</surname>
              <given-names>NA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Analysis of the Structural and Molecular Basis of Voltage-sensitive Sodium Channel Inhibition by the Spider Toxin Huwentoxin-IV (Î¼-TRTX-Hh2a)</article-title>
          <source>Journal of Biological Chemistry</source>
          <year>2013</year>
          <volume>288</volume>
          <fpage>22707</fpage>
          <lpage>22720</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M113.461392</pub-id>
          <?supplied-pmid 23760503?>
          <pub-id pub-id-type="pmid">23760503</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arnold</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bordoli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kopp</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schwede</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling</article-title>
          <source>Bioinformatics</source>
          <year>2006</year>
          <volume>22</volume>
          <fpage>195</fpage>
          <lpage>201</lpage>
          <pub-id pub-id-type="doi">10.1093/bioinformatics/bti770</pub-id>
          <?supplied-pmid 16301204?>
          <pub-id pub-id-type="pmid">16301204</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gilchrist</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Van Petegem</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bosmans</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Crystallographic insights into sodium-channel modulation by the beta4 subunit</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>2013</year>
          <volume>110</volume>
          <fpage>E5016</fpage>
          <lpage>E5024</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1314557110</pub-id>
          <?supplied-pmid 24297919?>
          <pub-id pub-id-type="pmid">24297919</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>He</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Soderlund</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Differential state-dependent modification of rat Nav1.6 sodium channels expressed in human embryonic kidney (HEK293) cells by the pyrethroid insecticides tefluthrin and deltamethrin</article-title>
          <source>Toxicology and Applied Pharmacology</source>
          <year>2011</year>
          <volume>257</volume>
          <fpage>377</fpage>
          <lpage>387</lpage>
          <pub-id pub-id-type="doi">10.1016/j.taap.2011.09.021</pub-id>
          <?supplied-pmid 21983428?>
          <pub-id pub-id-type="pmid">21983428</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <mixed-citation publication-type="other">Goldin, A. L. In <italic>Expression and Analysis of Recombinant Ion Channels: From Structural Studies to Pharmacological Screening</italic> (eds Derek J. Trezise, Jeffrey J. Clare) 1â25 (Wiley-VCH Verlag, Weinheim, 2006).</mixed-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Witchel</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Milnes</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Mitcheson</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Hancox</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Troubleshooting problems with <italic>in vitro</italic> screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes</article-title>
          <source>Journal of Pharmacological and Toxicological Methods</source>
          <year>2002</year>
          <volume>48</volume>
          <fpage>65</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="doi">10.1016/S1056-8719(03)00041-8</pub-id>
          <?supplied-pmid 14565563?>
          <pub-id pub-id-type="pmid">14565563</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li-Smerin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Swartz</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Localization and molecular determinants of the Hanatoxin receptors on the voltage-sensing domains of a K(+) channel</article-title>
          <source>J. Gen. Physiol.</source>
          <year>2000</year>
          <volume>115</volume>
          <fpage>673</fpage>
          <lpage>684</lpage>
          <pub-id pub-id-type="doi">10.1085/jgp.115.6.673</pub-id>
          <?supplied-pmid 10828242?>
          <pub-id pub-id-type="pmid">10828242</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klint</surname>
              <given-names>JK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Seven novel modulators of the analgesic target NaV1.7 uncovered using a high-throughput venom-based discovery approach</article-title>
          <source>British Journal of Pharmacology</source>
          <year>2015</year>
          <volume>172</volume>
          <fpage>2445</fpage>
          <lpage>2458</lpage>
          <pub-id pub-id-type="doi">10.1111/bph.13081</pub-id>
          <?supplied-pmid 25754331?>
          <pub-id pub-id-type="pmid">25754331</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vetter</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Characterisation of Nav types endogenously expressed in human SH-SY5Y neuroblastoma cells</article-title>
          <source>Biochemical Pharmacology</source>
          <year>2012</year>
          <volume>83</volume>
          <fpage>1562</fpage>
          <lpage>1571</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bcp.2012.02.022</pub-id>
          <?supplied-pmid 22410003?>
          <pub-id pub-id-type="pmid">22410003</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Felts</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Yokoyama</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dib-Hajj</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Waxman</surname>
              <given-names>SG</given-names>
            </name>
          </person-group>
          <article-title>Sodium channel alpha-subunit mRNAs I, II, III, NaG, Na6 and hNE (PN1): different expression patterns in developing rat nervous system</article-title>
          <source>Brain Res Mol Brain Res</source>
          <year>1997</year>
          <volume>45</volume>
          <fpage>71</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="doi">10.1016/S0169-328X(96)00241-0</pub-id>
          <?supplied-pmid 9105672?>
          <pub-id pub-id-type="pmid">9105672</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waxman</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Kocsis</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy</article-title>
          <source>J Neurophysiol</source>
          <year>1994</year>
          <volume>72</volume>
          <fpage>466</fpage>
          <lpage>470</lpage>
          <?supplied-pmid 7965028?>
          <pub-id pub-id-type="pmid">7965028</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Black</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Upregulation of a Silent Sodium Channel After Peripheral, but not Central, Nerve Injury in DRG Neurons</article-title>
          <source>Journal of Neurophysiology</source>
          <year>1999</year>
          <volume>82</volume>
          <fpage>2776</fpage>
          <lpage>2785</lpage>
          <?supplied-pmid 10561444?>
          <pub-id pub-id-type="pmid">10561444</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Gu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y-Q</given-names>
            </name>
            <name>
              <surname>Tao</surname>
              <given-names>Y-X</given-names>
            </name>
          </person-group>
          <article-title>Are voltage-gated sodium channels on the dorsal root ganglion involved in the development of neuropathic pain?</article-title>
          <source>Molecular Pain</source>
          <year>2011</year>
          <volume>7</volume>
          <fpage>16</fpage>
          <?supplied-pmid 21345196?>
          <pub-id pub-id-type="pmid">21345196</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murray</surname>
              <given-names>JK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Engineering Potent and Selective Analogues of GpTx-1, a Tarantula Venom Peptide Antagonist of the NaV1.7 Sodium Channel</article-title>
          <source>Journal of Medicinal Chemistry</source>
          <year>2015</year>
          <volume>58</volume>
          <fpage>2299</fpage>
          <lpage>2314</lpage>
          <pub-id pub-id-type="doi">10.1021/jm501765v</pub-id>
          <?supplied-pmid 25658507?>
          <pub-id pub-id-type="pmid">25658507</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tao</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Molecular determinant for the tarantula toxin Jingzhaotoxin-I slowing the fast inactivation of voltage-gated sodium channels</article-title>
          <source>Toxicon</source>
          <year>2016</year>
          <volume>111</volume>
          <fpage>13</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="doi">10.1016/j.toxicon.2015.12.009</pub-id>
          <?supplied-pmid 26721415?>
          <pub-id pub-id-type="pmid">26721415</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Jingzhaotoxin-II, a novel tarantula toxin preferentially targets rat cardiac sodium channel</article-title>
          <source>Biochemical Pharmacology</source>
          <year>2008</year>
          <volume>76</volume>
          <fpage>1716</fpage>
          <lpage>1727</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bcp.2008.09.008</pub-id>
          <?supplied-pmid 18840410?>
          <pub-id pub-id-type="pmid">18840410</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The tarantula toxin jingzhaotoxin-XI (Îº-theraphotoxin-Cj1a) regulates the activation and inactivation of the voltage-gated sodium channel Nav1.5</article-title>
          <source>Toxicon</source>
          <year>2014</year>
          <volume>92</volume>
          <fpage>6</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1016/j.toxicon.2014.09.002</pub-id>
          <?supplied-pmid 25240294?>
          <pub-id pub-id-type="pmid">25240294</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCormack</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels</article-title>
          <source>Proceedings of the National Academy of Sciences</source>
          <year>2013</year>
          <volume>110</volume>
          <fpage>E2724</fpage>
          <lpage>E2732</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1220844110</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Escoubas</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Diochot</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>CÃ©lÃ©rier</surname>
              <given-names>M-L</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lazdunski</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Novel Tarantula Toxins for Subtypes of Voltage-Dependent Potassium Channels in the Kv2 and Kv4 Subfamilies</article-title>
          <source>Molecular Pharmacology</source>
          <year>2002</year>
          <volume>62</volume>
          <fpage>48</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="doi">10.1124/mol.62.1.48</pub-id>
          <?supplied-pmid 12065754?>
          <pub-id pub-id-type="pmid">12065754</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <mixed-citation publication-type="other">Ahuja, S. <italic>et al</italic>. Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist. <italic>Science</italic><bold>350</bold>, aac5464, doi:10.1126/science.aac5464 (2015).</mixed-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cai</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mapping the interaction site for the tarantula toxin hainantoxin-IV (Î²-TRTX-Hn2a) in the voltage sensor module of domain II of voltage-gated sodium channels</article-title>
          <source>Peptides</source>
          <year>2015</year>
          <volume>68</volume>
          <fpage>148</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="doi">10.1016/j.peptides.2014.09.005</pub-id>
          <?supplied-pmid 25218973?>
          <pub-id pub-id-type="pmid">25218973</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structure and Function of Hainantoxin-III, a Selective Antagonist of Neuronal Tetrodotoxin-sensitive Voltage-gated Sodium Channels Isolated from the Chinese Bird Spider Ornithoctonus hainana</article-title>
          <source>Journal of Biological Chemistry</source>
          <year>2013</year>
          <volume>288</volume>
          <fpage>20392</fpage>
          <lpage>20403</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M112.426627</pub-id>
          <?supplied-pmid 23703613?>
          <pub-id pub-id-type="pmid">23703613</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klint</surname>
              <given-names>JK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Isolation, synthesis and characterization of Ï-TRTX-Cc1a, a novel tarantula venom peptide that selectively targets L-type CaV channels</article-title>
          <source>Biochemical Pharmacology</source>
          <year>2014</year>
          <volume>89</volume>
          <fpage>276</fpage>
          <lpage>286</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bcp.2014.02.008</pub-id>
          <?supplied-pmid 24561180?>
          <pub-id pub-id-type="pmid">24561180</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klint</surname>
              <given-names>JK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Production of Recombinant Disulfide-Rich Venom Peptides for Structural and Functional Analysis via Expression in the Periplasm of <italic>E. coli</italic></article-title>
          <source>PLoS One</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>e63865</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0063865</pub-id>
          <?supplied-pmid 23667680?>
          <pub-id pub-id-type="pmid">23667680</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chow</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cristofori-Armstrong</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Undheim</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rash</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Three Peptide Modulators of the Human Voltage-Gated Sodium Channel 1.7, an Important Analgesic Target, from the Venom of an Australian Tarantula</article-title>
          <source>Toxins</source>
          <year>2015</year>
          <volume>7</volume>
          <fpage>2494</fpage>
          <lpage>513</lpage>
          <pub-id pub-id-type="doi">10.3390/toxins7072494</pub-id>
          <?supplied-pmid 26134258?>
          <pub-id pub-id-type="pmid">26134258</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mobli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Bermel</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Hoch</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>A non-uniformly sampled 4D HCC(CO)NH-TOCSY experiment processed using maximum entropy for rapid protein sidechain assignment</article-title>
          <source>Journal of Magnetic Resonance</source>
          <year>2010</year>
          <volume>204</volume>
          <fpage>160</fpage>
          <lpage>164</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jmr.2010.02.012</pub-id>
          <?supplied-pmid 20299257?>
          <pub-id pub-id-type="pmid">20299257</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mobli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maciejewski</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Gryk</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Hoch</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>An automated tool for maximum entropy reconstruction of biomolecular NMR spectra</article-title>
          <source>Nat Methods</source>
          <year>2007</year>
          <volume>4</volume>
          <fpage>467</fpage>
          <lpage>468</lpage>
          <pub-id pub-id-type="doi">10.1038/nmeth0607-467</pub-id>
          <?supplied-pmid 17538627?>
          <pub-id pub-id-type="pmid">17538627</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bartels</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Billeter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Guntert</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wuthrich</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>The program XEASY for computer-supported NMR spectral analysis of biological macromolecules</article-title>
          <source>Journal of biomolecular NMR</source>
          <year>1995</year>
          <volume>6</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00417486</pub-id>
          <?supplied-pmid 22911575?>
          <pub-id pub-id-type="pmid">22911575</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <mixed-citation publication-type="other">Goddard, T. D. &amp; Kneller, D. G. <italic>SPARKY 3, NMR Assignment and Integration Software</italic> (University of California, San Francisco) https://www.cgl.ucsf.edu/home/sparky/ (2008).</mixed-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murali</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Napier</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Rycroft</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Christie</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Opioid-related (ORL1) receptors are enriched in a subpopulation of sensory neurons and prolonged activation produces no functional loss of surface N-type calcium channels</article-title>
          <source>The Journal of Physiology</source>
          <year>2012</year>
          <volume>590</volume>
          <fpage>1655</fpage>
          <lpage>1667</lpage>
          <pub-id pub-id-type="doi">10.1113/jphysiol.2012.228429</pub-id>
          <?supplied-pmid 22371475?>
          <pub-id pub-id-type="pmid">22371475</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seltzer</surname>
              <given-names>Ze</given-names>
            </name>
            <name>
              <surname>Dubner</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shir</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury</article-title>
          <source>Pain</source>
          <year>1990</year>
          <volume>43</volume>
          <fpage>205</fpage>
          <lpage>218</lpage>
          <pub-id pub-id-type="doi">10.1016/0304-3959(90)91074-S</pub-id>
          <?supplied-pmid 1982347?>
          <pub-id pub-id-type="pmid">1982347</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <mixed-citation publication-type="other">Meir, A., Cherki, R. S., Kolb, E., Langut, Y. &amp; Bajayo, N. Novel peptides isolated from spider venom, and uses thereof. (2011).</mixed-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Middleton</surname>
              <given-names>RE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Two tarantula peptides inhibit activation of multiple sodium channels</article-title>
          <source>Biochemistry</source>
          <year>2002</year>
          <volume>41</volume>
          <fpage>14734</fpage>
          <lpage>14747</lpage>
          <pub-id pub-id-type="doi">10.1021/bi026546a</pub-id>
          <?supplied-pmid 12475222?>
          <pub-id pub-id-type="pmid">12475222</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peng</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shu</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Function and Solution Structure of Huwentoxin-IV, a Potent Neuronal Tetrodotoxin (TTX)-sensitive Sodium Channel Antagonist from Chinese Bird Spider Selenocosmia huwena</article-title>
          <source>Journal of Biological Chemistry</source>
          <year>2002</year>
          <volume>277</volume>
          <fpage>47564</fpage>
          <lpage>47571</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M204063200</pub-id>
          <?supplied-pmid 12228241?>
          <pub-id pub-id-type="pmid">12228241</pub-id>
        </element-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>Y-C</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>S-P</given-names>
            </name>
          </person-group>
          <article-title>Purification and characterization of Hainantoxin-V, a tetrodotoxin-sensitive sodium channel inhibitor from the venom of the spider Selenocosmia hainana</article-title>
          <source>Toxicon</source>
          <year>2003</year>
          <volume>41</volume>
          <fpage>643</fpage>
          <lpage>650</lpage>
          <pub-id pub-id-type="doi">10.1016/S0041-0101(02)00280-5</pub-id>
          <?supplied-pmid 12727268?>
          <pub-id pub-id-type="pmid">12727268</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>